GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration.
Ontology highlight
ABSTRACT: Glucagon-like peptide-1 receptor (GLP1R) agonists and dipeptidyl peptidase 4 inhibitors are widely prescribed diabetes drugs due to their ability to stimulate insulin secretion from remaining β cells and to reduce caloric intake. Unfortunately, they fail to increase human β cell proliferation. Small-molecule inhibitors of dual-specificity tyrosine-regulated kinase 1A (DYRK1A) are able to induce adult human β cell proliferation, but rates are modest (~2%), and their specificity to β cells is limited. Here, we provide evidence that combining any member of the GLP1R agonist class with any member of the DYRK1A inhibitor class induces a synergistic increase in human β cell replication (5 to 6%) accompanied by an actual increase in numbers of human β cells. GLP1R agonist-DYRK1A inhibitor synergy
SUBMITTER: Ackeifi C
PROVIDER: S-EPMC9945936 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA